Efficacy
spasticity, visual analog pain
SECONDARY
All measures recorded at baseline, end-of-therapy, and follow-up assessments are
reported in Results for Outcome Measures for FitMi and Conventional Therapy
Groups.Abbreviations: BL, baseline; EOT, end-of-therapy; FU, follow-up;
UEFM, Upper Extremity Fugl–Meyer; MAS, Modified Ashworth scale for
spasticity; VAP, visual analog pain; MAL, motor activity log;
EQ-5D-3L, European Quality of Life five dimensions, three levels;
EQ-VAS, EuroQol Visual Analog Scale.For measures with a baseline assessment, the change from baseline to
follow-up was calculated. For each measure, the change was compared
between groups using unpaired, two-tailed Indicates a significant difference using the corrected α-value for
that assessment.For the primary outcome measure, the average change in UEFM from baseline to
follow-up for participants in the FitMi group (n = 14) was 8.0 ± 4.6 compared to
an average change of 3.0 ± 6.1 for participants in the conventional therapy
group (n = 11), a significant difference with a large effect size
((A) Average change in Upper Extremity Fugl–Meyer (UEFM) score for FitMi
group and conventional therapy group at each assessment. The error bars
represent 1 SD. (BL = Baseline) FitMi participants improved
significantly more than the conventional therapy group. *Indicates a
significant within-group difference between UEFM scores at each time
point compared to baseline (Abbreviations: EOT, end-of-therapy; FU, follow-up.The 2 groups’ scores did not change significantly differently for any of the
secondary outcomes.Mixed model ANOVA analysis for UFEM scores found a significant time effect
(